StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
EVEXIA.BO$1.79-0.56%
Fair $1.79+0.0%

EVEXIA.BO

Evexia Lifecare Ltd

Consumer Defensive / Packaged FoodsBSE

$1.79

-0.01 (-0.56%)

Fairly Valued+0.0%Fair Value $1.79Fund rank 24/100 · Data gapFallback financials|
SA 49/C
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-44.1M · quality 43.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 5/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

49/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 0.4%, below the 5% threshold
Thesis & Journal · EVEXIA.BOLocal privado en este navegador · Evexia Lifecare Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.4B

P/E

179.0x

↑

EV/EBITDA

117.3x

↑

ROE

0.4%

↓

Gross Margin

5.2%

↓

Debt/Equity

0.01

↓
52-Week Range$2
$0$3

TradingView lightweight chart

EVEXIA.BO price, volumen y niveles de valoración

Último $1.790Periodo -46.2%
Fair value: $1.790

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+16.6%

FCF CAGR

—

FCF margin

-24.2%

FCF / Net income

-16.48x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.10B · net income $16.2M · FCF $-267.1M

2023-FY → 2026-FY

Gross margin

5.2%-0.4% pts

Operating margin

2.0%+1.6% pts

Net margin

1.5%+0.5% pts

FCF margin

-24.2%-16.2% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$1.10B$1.10B$865.9M$549.2M$695.5M
Net Income$16.2M$16.2M$4.1M$13.8M$6.7M
EBITDA$28.7M$28.7M$17.5M$27.0M$24.6M
EPS——0.000.020.01
Gross Margin5.2%5.2%4.4%7.7%5.6%
Operating Margin2.0%2.0%1.3%1.4%0.4%
Net Margin1.5%1.5%0.5%2.5%1.0%
Balance Sheet
Debt/Equity0.010.010.815.307.79
Cash Flow
Free Cash Flow$-267.1M$-267.1M$-44.1M$167.6M$-55.9M
Returns
ROE0.4%0.4%0.1%1.1%0.7%
Valuation
P/E179.00179.001295.00133.00187.00
EV/EBITDA117.34117.34518.40323.51337.31
P/B0.770.771.161.461.38
Growth & Yield
Revenue Growth27.4%27.4%57.7%-21.0%—
EPS Growth——-90.0%100.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -29.0%

Total return

-29.0%

Start / end P/E

n/dx → n/dx

EPS bridge

0.00 → n/d

Residual

-29.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-29.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.